Abstract
Thyroid cancer may express estrogen receptors (ERs) and various grades of peri-tumor inflammation. The aim of the study was to evaluate the expression of ERs in relation to the TNM stage and peri-tumor inflammatory infiltrate in differentiated thyroid cancers. 127 patients (109 females, 18 males) with differentiated thyroid cancer (T1 = 91, T2 = 18, T3 = 11, T4 = 7) were evaluated. In tumors and in the correspondent extra-tumor parenchyma, ERs expression was evaluated by immunohistochemistry. In 114 tumors and correspondent peri-tumor tissues, the presence of inflammatory infiltration was also recorded. ER-alpha expression was higher in clinical than in incidental tumors of the T1 subgroup (p = 0.037), and was associated with capsular invasion in T2 tumors (p < 0.0001). ER-beta expression was negatively associated with vascular invasion in T1 (p = 0.005) and T2 tumors (p = 0.015). No significant relationship between ERs expression and tumor phenotype emerged in T3 and T4 subgroups. Tumors without inflammatory cell infiltrate showed a higher expression of both ER-alpha (p = 0.035) and ER-beta (p = 0.026) than the ones with inflammatory infiltrate. The relationship between tumor phenotype and ERs expression did not vary in the presence or absence of peri-tumor inflammatory infiltration. ER-alpha positivity and ER-beta negativity are associated with a more aggressive phenotype in both T1 and T2 thyroid cancers, suggesting that tumor biology may be more relevant than tumor size for cancer risk assessment. Inflammatory status is also associated with ERs expression, but not with tumor growth or phenotype.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
R. Bonacci, A. Pinchera, P. Fierabracci, A. Gigliotti, L. Grasso, C. Giani, Relevance of estrogen and progesterone receptors enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue. J. Endocrinol. Invest. 19(3), 159–164 (1996)
F. Magri, V. Capelli, M. Rotondi, P. Leporati, L. La Manna, R. Ruggiero, A. Malovini, R. Bellazzi, L. Villani, L. Chiovato, Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient’s risk. Endocr. Relat. Cancer 19(4), 463–471 (2012)
G.G. Chen, A.C. Vlantis, Q. Zeng, C.A. van Hasselt, Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr. Cancer Drug Targets 8(5), 367–377 (2008)
Q. Zeng, G.G. Chen, A.C. Vlantis, C.A. van Hasselt, Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif. 40(6), 921–935 (2007)
Q. Zeng, G. Chen, A. Vlantis, G. Tse, C. van Hasselt, The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J. Pathol. 214(4), 425–433 (2008)
A. Heikkila, J. Hagstrom, H. Maenpaa, J. Louhimo, P. Siironen, I. Heiskanen, C. Haglund, J. Arola, Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome. Thyroid 23(4), 456–465 (2013)
S. Xu, G. Chen, W. Peng, K. Renko, M. Derwahl, Oestrogen action on thyroid progenitor cells: relevant for the pathogenesis of thyroid nodules? J. Endocrinol. 218(1), 125–133 (2013)
M.L. Lee, G.G. Chen, A.C. Vlantis, G.M. Tse, B.C. Leung, C.A. van Hasselt, Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J. 11(2), 113–121 (2005)
D. Manole, B. Schildknecht, B. Gosnell, E. Adams, M. Derwahl, Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J. Clin. Endocrinol. Metab. 86(3), 1072–1077 (2001)
S. Rajoria, R. Suriano, A. Shanmugam, Y.L. Wilson, S.P. Schantz, J. Geliebter, R.K. Tiwari, Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 20(1), 33–41 (2010)
M. Tafani, E. De Santis, L. Coppola, G.A. Perrone, I. Carnevale, A. Russo, B. Pucci, A. Carpi, M. Bizzarri, M.A. Russo, Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. Biomed. Pharmacother. 68(1), 1–5 (2014)
J.S. Lewis-Wambi, V.C. Jordan, Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 11(3), 206 (2009)
M. Pradhan, S.C. Baumgarten, L.A. Bembinster, J. Frasor, CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter. Mol. Cell. Biol. 32(2), 569–575 (2012)
R. Chu, A. van Hasselt, A.C. Vlantis, E.K. Ng, S.Y. Liu, M.D. Fan, S.K. Ng, A.B. Chan, Z. Liu, X.Y. Li et al., The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer. Cancer 120(1), 142–153 (2014)
D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011)
F. Liotti, C. Visciano, R.M. Melillo, Inflammation in thyroid oncogenesis. Am J Cancer Res 2(3), 286–297 (2012)
L.L. Cunha, M.A. Marcello, L.S. Ward, The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocr. Relat. Cancer 21(3), 85–103 (2013)
A. Proietti, C. Ugolini, R.M. Melillo, G. Crisman, R. Elisei, M. Santoro, M. Minuto, P. Vitti, P. Miccoli, F. Basolo, Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid 21(11), 1209–1215 (2011)
E. De Santis, M. Di Vito, G.A. Perrone, E. Mari, M. Osti, E. De Antoni, L. Coppola, M. Tafani, A. Carpi, M.A. Russo, Overexpression of pro-inflammatory genes and down-regulation of SOCS-1 in human PTC and in hypoxic BCPAP cells. Biomed. Pharmacother. 67(1), 7–16 (2013)
M. Clemons, P. Goss, Estrogen and the risk of breast cancer. N. Engl. J. Med. 344(4), 276–285 (2001)
D. Rades, C. Setter, O. Dahl, S.E. Schild, F. Noack, The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for non-small cell lung cancer. Cancer 118(1), 157–163 (2011)
M. Barone, K. Lofano, N. De Tullio, R. Licino, F. Albano, A. Di Leo, Dietary, endocrine, and metabolic factors in the development of colorectal cancer. J Gastrointest Cancer 43(1), 13–19 (2012)
A. Bardin, N. Boulle, G. Lazennec, F. Vignon, P. Pujol, Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 11(3), 537–551 (2004)
Y. Huang, W. Dong, J. Li, H. Zhang, Z. Shan, W. Teng, Differential expression patterns and clinical significance of estrogen receptor-alpha and beta in papillary thyroid carcinoma. BMC Cancer 14, 383 (2014)
S. Chu, Y. Nishi, T. Yanase, H. Nawata, P.J. Fuller, Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Mol. Endocrinol. 18(8), 1919–1928 (2004)
F. Pacifico, A. Leonardi, Role of NF-kappaB in thyroid cancer. Mol. Cell. Endocrinol. 321(1), 29–35 (2010)
W.H. Sun, E.T. Keller, B.S. Stebler, W.B. Ershler, Estrogen inhibits phorbol ester-induced I kappa B alpha transcription and protein degradation. Biochem Biophys Res Commun 244(3), 691–695 (1998)
Conflict of interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Magri, F., Capelli, V., Gaiti, M. et al. ER-alpha and ER-beta expression in differentiated thyroid cancer: relation with tumor phenotype across the TNM staging and peri-tumor inflammation. Endocrine 49, 429–435 (2015). https://doi.org/10.1007/s12020-014-0457-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0457-x